REFERENCES
1. Goedert M. NEURODEGENERATION. Alzheimer's and Parkinson's diseases: The prion concept in relation to assembled Aβ, tau, and α-synuclein. Science 2015;349:1255555.
2. Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006;314:130-3.
3. Peng C, Gathagan RJ, Lee VM. Distinct α-Synuclein strains and implications for heterogeneity among α-Synucleinopathies. Neurobiol Dis 2018;109:209-18.
4. Peng C, Gathagan RJ, Covell DJ, et al. Cellular milieu imparts distinct pathological α-synuclein strains in α-synucleinopathies. Nature 2018;557:558-63.
5. Lau A, So RWL, Lau HHC, et al. α-Synuclein strains target distinct brain regions and cell types. Nat Neurosci 2020;23:21-31.
6. Nonaka T, Masuda-Suzukake M, Arai T, et al. Prion-like properties of pathological TDP-43 aggregates from diseased brains. Cell Rep 2013;4:124-34.
7. Fitzpatrick AWP, Falcon B, He S, et al. Cryo-EM structures of tau filaments from Alzheimer's disease. Nature 2017;547:185-90.
8. Falcon B, Zhang W, Murzin AG, et al. Structures of filaments from Pick's disease reveal a novel tau protein fold. Nature 2018;561:137-40.
9. Falcon B, Zivanov J, Zhang W, et al. Novel tau filament fold in chronic traumatic encephalopathy encloses hydrophobic molecules. Nature 2019;568:420-3.
10. Schweighauser M, Shi Y, Tarutani A, et al. Structures of α-synuclein filaments from multiple system atrophy. Nature 2020;585:464-9.
11. Zhang W, Tarutani A, Newell KL, et al. Novel tau filament fold in corticobasal degeneration. Nature 2020;580:283-7.
12. Shi Y, Zhang W, Yang Y, et al. Structure-based classification of tauopathies. Nature 2021;598:359-63.
13. Arseni D, Hasegawa M, Murzin AG, et al. Structure of pathological TDP-43 filaments from ALS with FTLD. Nature 2022;601:139-43.
14. Yang Y, Arseni D, Zhang W, et al. Cryo-EM structures of amyloid-β 42 filaments from human brains. Science 2022;375:167-72.
15. Yang Y, Shi Y, Schweighauser M, et al. Structures of α-synuclein filaments from human brains with Lewy pathology. Nature 2022;610:791-5.
16. Van Deerlin VM, Sleiman PM, Martinez-Lage M, et al. Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet 2010;42:234-9.
17. Gallagher MD, Suh E, Grossman M, et al.
18. Harding SR, Bocchetta M, Gordon E, et al. The TMEM106B risk allele is associated with lower cortical volumes in a clinically diagnosed frontotemporal dementia cohort. J Neurol Neurosurg Psychiatry 2017;88:997-8.
19. Pottier C, Zhou X, Perkerson RB 3rd, et al. Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. Lancet Neurol 2018;17:548-58.
20. Tropea TF, Mak J, Guo MH, et al.
21. Hu Y, Sun JY, Zhang Y, et al. rs1990622 variant associates with Alzheimer's disease and regulates
22. Mao F, Robinson JL, Unger T, et al. TMEM106B modifies TDP-43 pathology in human ALS brain and cell-based models of TDP-43 proteinopathy. Acta Neuropathol 2021;142:629-42.
23. Cykowski MD, Arumanayagam AS, Powell SZ, et al. Patterns of amygdala region pathology in LATE-NC: subtypes that differ with regard to TDP-43 histopathology, genetic risk factors, and comorbid pathologies. Acta Neuropathol 2022;143:531-45.
24. Busch JI, Martinez-Lage M, Ashbridge E, et al. Expression of TMEM106B, the frontotemporal lobar degeneration-associated protein, in normal and diseased human brain. Acta Neuropathol Commun 2013;1:36.
25. Satoh J, Kino Y, Kawana N, et al. TMEM106B expression is reduced in Alzheimer's disease brains. Alzheimers Res Ther 2014;6:17.
26. Brady OA, Zheng Y, Murphy K, Huang M, Hu F. The frontotemporal lobar degeneration risk factor, TMEM106B, regulates lysosomal morphology and function. Hum Mol Genet 2013;22:685-95.
27. Schwenk BM, Lang CM, Hogl S, et al. The FTLD risk factor TMEM106B and MAP6 control dendritic trafficking of lysosomes. EMBO J 2014;33:450-67.
28. Klein ZA, Takahashi H, Ma M, et al. Loss of TMEM106B ameliorates lysosomal and frontotemporal dementia-related phenotypes in progranulin-deficient mice. Neuron 2017;95:281-296.e6.
29. Schweighauser M, Arseni D, Bacioglu M, et al. Age-dependent formation of TMEM106B amyloid filaments in human brains. Nature 2022;605:310-4.
30. Jiang YX, Cao Q, Sawaya MR, et al. Amyloid fibrils in FTLD-TDP are composed of TMEM106B and not TDP-43. Nature 2022;605:304-9.
31. Chang A, Xiang X, Wang J, et al. Homotypic fibrillization of TMEM106B across diverse neurodegenerative diseases. Cell 2022;185:1346-1355.e15.
32. Fan Y, Zhao Q, Xia W, et al. Generic amyloid fibrillation of TMEM106B in patient with Parkinson's disease dementia and normal elders. Cell Res 2022;32:585-8.
33. Lang CM, Fellerer K, Schwenk BM, et al. Membrane orientation and subcellular localization of transmembrane protein 106B (TMEM106B), a major risk factor for frontotemporal lobar degeneration. J Biol Chem 2012;287:19355-65.
34. Chen-Plotkin AS, Unger TL, Gallagher MD, et al.
35. Feng T, Sheng RR, Solé-Domènech S, et al. A role of the frontotemporal lobar degeneration risk factor TMEM106B in myelination. Brain 2020;143:2255-71.
36. Simons C, Dyment D, Bent SJ, et al. Care4Rare Consortium. A recurrent
37. Kang J, Lim L, Song J. TMEM106B, a risk factor for FTLD and aging, has an intrinsically disordered cytoplasmic domain. PLoS One 2018;13:e0205856.
38. Stagi M, Klein ZA, Gould TJ, Bewersdorf J, Strittmatter SM. Lysosome size, motility and stress response regulated by fronto-temporal dementia modifier TMEM106B. Mol Cell Neurosci 2014;61:226-40.
39. Busch JI, Unger TL, Jain N, Tyler Skrinak R, Charan RA, Chen-Plotkin AS. Increased expression of the frontotemporal dementia risk factor TMEM106B causes C9orf72-dependent alterations in lysosomes. Hum Mol Genet 2016;25:2681-97.
40. Solé-Domènech S, Cruz DL, Capetillo-Zarate E, Maxfield FR. The endocytic pathway in microglia during health, aging and Alzheimer's disease. Ageing Res Rev 2016;32:89-103.
41. Lie PPY, Nixon RA. Lysosome trafficking and signaling in health and neurodegenerative diseases. Neurobiol Dis 2019;122:94-105.
42. Hou Y, Dan X, Babbar M, et al. Ageing as a risk factor for neurodegenerative disease. Nat Rev Neurol 2019;15:565-81.
43. Mohandas E, Rajmohan V. Frontotemporal dementia: an updated overview. Indian J Psychiatry 2009; 51 Suppl 1(Suppl1):S65-9.
44. Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998;51:1546-54.
45. Goldman JS, Farmer JM, Van Deerlin VM, Wilhelmsen KC, Miller BL, Grossman M. Frontotemporal dementia: genetics and genetic counseling dilemmas. Neurologist 2004;10:227-34.
46. Mackenzie IR, Neumann M, Baborie A, et al. A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol 2011;122:111-3.
47. Lee EB, Porta S, Michael Baer G, et al. Expansion of the classification of FTLD-TDP: distinct pathology associated with rapidly progressive frontotemporal degeneration. Acta Neuropathol 2017;134:65-78.
48. Rohrer JD, Guerreiro R, Vandrovcova J, et al. The heritability and genetics of frontotemporal lobar degeneration. Neurology 2009;73:1451-6.
49. Huber N, Korhonen S, Hoffmann D, et al. Deficient neurotransmitter systems and synaptic function in frontotemporal lobar degeneration-Insights into disease mechanisms and current therapeutic approaches. Mol Psychiatry 2022;27:1300-9.
50. Majounie E, Renton AE, Mok K, et al. Chromosome 9-ALS/FTD Consortium. Frequency of the
51. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of
52. Renton AE, Majounie E, Waite A, et al. ITALSGEN Consortium. A hexanucleotide repeat expansion in
53. Cruchaga C, Graff C, Chiang HH, et al. Association of TMEM106B gene polymorphism with age at onset in granulin mutation carriers and plasma granulin protein levels. Arch Neurol 2011;68:581-6.
54. Finch N, Carrasquillo MM, Baker M, et al.
55. van der Zee J, Van Langenhove T, Kleinberger G, et al.
56. Li Z, Farias FHG, Dube U, et al. The
59. van Blitterswijk M, Mullen B, Nicholson AM, et al.
60. Deming Y, Cruchaga C.
61. Nicholson AM, Finch NA, Wojtas A, et al. TMEM106B p.T185S regulates TMEM106B protein levels: implications for frontotemporal dementia. J Neurochem 2013;126:781-91.
63. Lu RC, Wang H, Tan MS, Yu JT, Tan L. TMEM106B and APOE polymorphisms interact to confer risk for late-onset Alzheimer's disease in Han Chinese. J Neural Transm (Vienna) 2014;121:283-7.
64. Jun G, Ibrahim-Verbaas CA, Vronskaya M, et al. IGAP Consortium. A novel Alzheimer disease locus located near the gene encoding tau protein. Mol Psychiatry 2016;21:108-17.
65. Rutherford NJ, Carrasquillo MM, Li M, et al.
66. Milind N, Preuss C, Haber A, et al. Transcriptomic stratification of late-onset Alzheimer's cases reveals novel genetic modifiers of disease pathology. PLoS Genet 2020;16:e1008775.
67. Vass R, Ashbridge E, Geser F, et al. Risk genotypes at
68. Lemprière S. Frontotemporal dementia risk variant accelerates cognitive decline in Parkinson disease. Nat Rev Neurol 2019;15:307.
69. Manini A, Ratti A, Brusati A, et al.
70. Montenigro PH, Corp DT, Stein TD, Cantu RC, Stern RA. Chronic traumatic encephalopathy: historical origins and current perspective. Annu Rev Clin Psychol 2015;11:309-30.
71. McKee AC, Stern RA, Nowinski CJ, et al. The spectrum of disease in chronic traumatic encephalopathy. Brain 2013;136:43-64.
72. Bieniek KF, Ross OA, Cormier KA, et al. Chronic traumatic encephalopathy pathology in a neurodegenerative disorders brain bank. Acta Neuropathol 2015;130:877-89.
73. Cherry JD, Mez J, Crary JF, et al. Variation in
74. Nelson PT, Wang WX, Partch AB, et al. Reassessment of risk genotypes (
75. Dickson DW, Rademakers R, Nicholson AM, Schneider JA, Yu L, Bennett DA. The
76. Hokkanen SRK, Kero M, Kaivola K, et al. EClipSE Collaboration. Putative risk alleles for LATE-NC with hippocampal sclerosis in population-representative autopsy cohorts. Brain Pathol 2020;30:364-72.
77. Nelson PT, Dickson DW, Trojanowski JQ, et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain 2019;142:1503-27.
78. Culig L, Chu X, Bohr VA. Neurogenesis in aging and age-related neurodegenerative diseases. Ageing Res Rev 2022;78:101636.
79. Crary JF, Trojanowski JQ, Schneider JA, et al. Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol 2014;128:755-66.
80. Jellinger KA. Lewy body-related alpha-synucleinopathy in the aged human brain. J Neural Transm (Vienna) 2004;111:1219-35.
81. Marks SM, Lockhart SN, Baker SL, Jagust WJ. Tau and β-amyloid are associated with medial temporal lobe structure, function, and memory encoding in normal aging. J Neurosci 2017;37:3192-201.
82. Ren Y, van Blitterswijk M, Allen M, et al.
83. Yang HS, White CC, Klein HU, et al. Genetics of gene expression in the aging human brain reveal TDP-43 proteinopathy pathophysiology. Neuron 2020;107:496-508.e6.
84. Adams HH, Verhaaren BF, Vrooman HA, et al.
85. Goedert M, Spillantini MG, Cairns NJ, Crowther RA. Tau proteins of Alzheimer paired helical filaments: abnormal phosphorylation of all six brain isoforms. Neuron 1992;8:159-68.
86. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. Alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc Natl Acad Sci USA 1998;95:6469-73.
87. Spillantini MG, Crowther RA, Jakes R, Cairns NJ, Lantos PL, Goedert M. Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci Lett 1998;251:205-8.
88. Crowther RA, Daniel SE, Goedert M. Characterisation of isolated alpha-synuclein filaments from substantia nigra of Parkinson's disease brain. Neurosci Lett 2000;292:128-30.
89. Falcon B, Zhang W, Schweighauser M, et al. Tau filaments from multiple cases of sporadic and inherited Alzheimer's disease adopt a common fold. Acta Neuropathol 2018;136:699-708.
90. Brady OA, Zhou X, Hu F. Regulated intramembrane proteolysis of the frontotemporal lobar degeneration risk factor, TMEM106B, by signal peptide peptidase-like 2a (SPPL2a). J Biol Chem 2014;289:19670-80.
91. Tunyasuvunakool K, Adler J, Wu Z, et al. Highly accurate protein structure prediction for the human proteome. Nature 2021;596:590-6.
92. Li Y, Zhao C, Luo F, et al. Amyloid fibril structure of α-synuclein determined by cryo-electron microscopy. Cell Res 2018;28:897-903.
93. Li B, Ge P, Murray KA, et al. Cryo-EM of full-length α-synuclein reveals fibril polymorphs with a common structural kernel. Nat Commun 2018;9:3609.
94. Guerrero-Ferreira R, Taylor NM, Arteni AA, et al. Two new polymorphic structures of human full-length alpha-synuclein fibrils solved by cryo-electron microscopy. Elife 2019:8.
95. Jellinger KA. Lewy body/alpha-synucleinopathy in schizophrenia and depression: a preliminary neuropathological study. Acta Neuropathol 2009;117:423-7.
96. Yu L, De Jager PL, Yang J, Trojanowski JQ, Bennett DA, Schneider JA. The
97. Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211.
98. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82:239-59.
99. Premi E, Formenti A, Gazzina S, et al. Effect of
100. Premi E, Grassi M, van Swieten J, et al. Genetic FTD Initiative (GENFI). Cognitive reserve and
101. Llibre-Guerra JJ, Lee SE, Suemoto CK, et al. A novel temporal-predominant neuro-astroglial tauopathy associated with
102. Murray ME, Cannon A, Graff-Radford NR, et al. Differential clinicopathologic and genetic features of late-onset amnestic dementias. Acta Neuropathol 2014;128:411-21.
103. Hong S, Dobricic V, Ohlei O, et al. Alzheimer's Disease Neuroimaging Initiative (ADNI). TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels. Alzheimers Dement 2021;17:1628-40.
